All In Biotech

Drug Trial Radar · NCT05784688

Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

A Phase 1b/2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGFβR Serine/Threonine Kinase Inhibitor, Administered in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Mar 10, 2023

Primary completion

Dec 2026

Study completion Dec 2028

Sponsor

Lead sponsor
TiumBio Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Mar 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors.

Conditions

  • Solid Tumor
  • Biliary Tract Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Colorectal Cancer

Interventions

  • TU2218 + KEYTRUDA® (Pembrolizumab)Drug

    TU2218: Orally administered KEYTRUDA® (Pembrolizumab): Intravenously administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: To determine the Recommended Phase 2 Dose of the Combination (RP2DC) of TU2218 given with Pembrolizumab in selected advanced solid tumorsTime frame: During the first 21-day period (Cycle 1)
  2. Phase 2a: To evaluate the efficacy of TU2218 by evaluating the Overall Response rate (ORR) of TU2218 administered in combination with Pembrolizumab in selected advanced solid tumorsTime frame: 24 weeks

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • NEXT Oncology

    San Antonio, Texas · Active not recruiting

  • Hope Cancer Center

    Tyler, Texas · Active not recruiting

  • Medical Oncology

    Spokane, Washington · Active not recruiting

  • CHA University Bundang Medical Center

    Seongnam, South Korea · Recruiting

  • Seoul National University Bundang Hospital

    Seongnam, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Severance Hospital

    Seoul, South Korea · Recruiting

  • The Catholic University of Korea Seoul St. Mary Hospital

    Seoul, South Korea · Recruiting

  • The Catholic University of Korea St. Vincent's Hospital

    Suwon, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.